Front Page-Rx

Last week, California enacted the first-in-the-nation state law to combat pay-for-delay deals between brand-name and generic pharmaceutical drug manufacturers. In a pay-for-delay deal, a brand manufacturer pays a generic competitor to settle patent litigation and keep the lower-cost version of the drug off the market. Delaying market entry of generic drugs limits competition and can […]

Read More
  • State Health Policy Blog

    Nevada Fines Rx Manufacturers $17.4 Million for Failing to Explain Diabetes Medications’ Price Hikes

    Last week, Nevada fined 21 pharmaceutical companies $17.4 million for failing to submit a report explaining recent, significant price hikes to essential diabetes drugs, as required by the state’s drug cost transparency law. Faced with drug price increases far outpacing rates of inflation, states across the country are enacting transparency laws designed to shed light […]

    Read More
  • State Health Policy Blog

    Legal Landmines in Drug Pricing Laws: What’s a State To Do?

    Every state in the nation has proposed bills to limit pharmaceutical drug prices and the pace of that legislative work increases each year. The usual responses from pharmaceutical manufacturers and their allies is to threaten to reduce their investments in new drug research and development and challenge the new state laws in federal court. In […]

    Read More
  • Publications

    Navigating Legal Challenges to State Efforts to Control Drug Prices: Pharmacy Benefit Manager Regulation, Anti-Price-Gouging Laws, and Price Transparency

    States have passed an unprecedented number of laws addressing drug prices over the past few years and some have faced legal challenges. This NASHP legal brief explores those challenges and highlights how states can develop effective drug pricing policies to avoid legal challenges. The brief analyzes the arguments industry groups have made against pharmacy benefit manager regulations, […]

    Read More
  • State Health Policy Blog

    A New State Tool to Manage Drug Costs: Experts Share Insights into Outcome-Based Contracts for Medicaid Pharmacy Claims

    Colorado and Michigan have joined Oklahoma to become the nation’s pioneering states with approved State Plan Amendments (SPAs) that enable Medicaid alternative payment models (APMs) for prescription drugs in the form of outcome-based contracts with pharmaceutical manufacturers. In early May, state experts from Oklahoma, Colorado, and Michigan shared their experiences implementing their APMs during a […]

    Read More
  • State Health Policy Blog

    Delaware Takes on High Prescription Drug Costs by Leveraging Public Purchasers

    Delaware’s state Legislature has established the Interagency Pharmaceuticals Purchasing Study Group to recommend steps to leverage bulk purchasing of drugs to effectively negotiate lower prices by using interagency and multistate purchasing contracts, and other approaches. The measure easily passed the House on a voice vote and unanimously passed the Senate. The study group has an […]

    Read More
  • State Health Policy Blog

    NASHP Updates Model Drug Price Transparency Legislation, Featuring a Common Data Set for Cross-State Comparisons and Stronger Enforcement

    As drug price transparency measures proliferate across states, the National Academy of State Health Policy (NASHP) has released revised model transparency legislation featuring a common data set to reduce reporter burden and yield standardized, actionable data that will be comparable across states.  The data — to be reported by manufacturers, pharmacy benefit managers (PBMs), wholesalers, and insurers — will […]

    Read More
    April 23, 2019 | Filed under: Front Page, Front Page-Rx, Maine, State Health Policy Blog

  • State Health Policy Blog

    New Law Enables New Mexico to Leverage State Purchasing Power to Lower Rx Spending

    New Mexico Gov. Lujan Grisham recently signed into law SB 131, establishing a state Interagency Pharmacy Purchasing Council to leverage public purchasing power by reviewing and coordinating cost-containment strategies through procurement of pharmaceuticals, pharmaceutical benefits, and pooling of risk among state agencies. Cosponsored by state Sen. Jeff Steinborn* and Rep. Joanne Farrary, the law also […]

    Read More
  • Publications

    State Initiatives Using Purchasing Power to Achieve Drug Cost Containment

    This report focuses on several state purchasing strategies designed to achieve concessions in negotiations with drug manufacturers and in other parts of the prescription drug supply chain. The highlighted strategies include intrastate actions, which combine state agencies’ purchases of drugs to improve their negotiating clout, and interstate activities, such as multi-state organizations that unite to […]

    Read More
    April 15, 2019 | Filed under: Featured-Rx, Front Page-Rx, Medicaid, Payment Reform, Publications

  • Publications

    Cross-Agency Strategies to Curb Health Care Costs: Leveraging State Purchasing Power

    Rising health care costs are an intractable problem in the United States, but states, faced with balanced budget requirements and growing voter concern, aren’t waiting for a federal solution. This report explores state initiatives to curb health care costs by:  Leveraging Medicare’s well-established reimbursement rates as reference prices for state employee plans to address rising […]

    Read More